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Summary
Objective: Five double-blind, randomized, saline-controlled trials (RCTs) were included in the United States marketing application for an intra-
articular hyaluronan (IA-HA) product for the treatment of osteoarthritis (OA) of the knee. We report an integrated analysis of the primary Case
Report Form (CRF) data from these trials.
Method: Trials were similar in design, patient population and outcome measures e all included the Leque`sne Algofunctional Index (LI), a val-
idated composite index of pain and function, evaluating treatment over 3 months. Individual patient data were pooled; a repeated measures
analysis of covariance was performed in the intent-to-treat (ITT) population. Analyses utilized both ﬁxed and random effects models. Safety
data from the ﬁve RCTs were summarized.
Results: A total of 1155 patients with radiologically conﬁrmed knee OA were enrolled: 619 received three or ﬁve IA-HA injections; 536 received
‘‘placebo’’ saline injections. In the active and control groups, mean ages were 61.8 and 61.4 years; 62.4% and 58.8% were women; baseline
total Leque`sne scores 11.03 and 11.30, respectively. Integrated analysis of the pooled data set found a statistically signiﬁcant reduction
(P< 0.001) in total Leque`sne score with hyaluronan (HA) (2.68) vs placebo (2.00); estimated difference 0.68 (95% CI: 0.56 to
0.79), effect size 0.20. Additional modeling approaches conﬁrmed robustness of the analyses.
Conclusions: This integrated analysis demonstrates that multiple design factors inﬂuence the results of RCTs assessing efﬁcacy of intra-
articular (IA) therapies, and that integrated analyses based on primary data differ from meta-analyses using transformed data.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Intra-articular hyaluronan (IA-HA) products have been
licensed in the United States for treatment of knee osteoar-
thritis (OA) since 1997 and in other parts of the world since
1987. For United States marketing approval, the FDA has
required that IA-HA products submit evidence of safety
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2006.859and efﬁcacy from double-blind, randomized controlled trials
(RCTs), typically using intra-articular (IA) saline injections
as the ‘‘placebo’’ control. Despite this standard, IA-HA treat-
ment for knee OA continues to be controversial, primarily
because trials examining this therapy have not been uni-
formly well-designed, yielding unimpressive results as to
the magnitude and signiﬁcance of active treatment com-
pared with control1e3.
Divergent interpretations from three recent meta-analyses
have added to this controversy4e6. Although all report treat-
ment effects of IA-HA compared with saline injections to be
statistically signiﬁcant, they differ with respect to calculated
effect sizes and interpretation of clinical importance. Meta-
analyses based on publications from RCTs are limited by
reliance on extraction of information from summarized
data and abbreviated statistics. Differing data extraction
860 V. Strand et al.: Hyaluronan integrated analysisprocedures and statistical methodology may yield disparate
conclusions even when evaluating the same RCT reports.
This appears especially true in meta-analyses of IA-HA
RCTs, which necessarily must account for diverse trial de-
signs, control treatments, outcome measures and evalua-
tion time points, and data pooled across products with
differing compositions and physical properties. Because hy-
aluronan (HA) is a natural polymer, IA-HA products can vary
broadly in molecular weight and purity, and may also
include synthetic crosslinks. These differences may be
clinically relevant, particularly with respect to safety
characteristics7,8.
To supplement evidence provided by recent meta-analyses
of IA-HA treatment, an integrated analysis of ﬁve RCTs
examining a single IA-HA product is presented. Analyses
were based on individual patient data from Case Report
Forms (CRFs), assembled into a data set for the pooled
intent-to-treat (ITT) population, and accepted by the FDA
as part of a marketing application supporting a single
IA-HA product9. This provides a comparison that avoids
some limitations inherent to meta-analyses, because it
circumvents the need for any type of data transformation.
Importantly, these analyses provide an overview of the
type of evidence used by the FDA to assess the safety
and effectiveness of an approved IA-HA product and dem-
onstrate that even similarly designed RCTs of a single prod-
uct may yield diverse conclusions.
Results from three of the ﬁve RCTs are published, includ-
ing the pivotal trial in 2004; two reported statistical superior-
ity for IA-HA treatment (Table I)10e12. In the trial without
statistical signiﬁcance, a prospectively deﬁned subgroup
analysis in patients >65 years old with baseline Leque`sne
Index (LI) scores >10 statistically favored active treatment.
Although the remaining two RCTs have not been published
in peer-reviewed literature, complete clinical and statistical
reports were submitted to the FDA and are included in the
analyses presented here.
Differences between peer review and regulatory review
processes are not widely recognized. Clinical trials
accepted for FDA review include multiple procedures to en-
sure scientiﬁc integrity of the data and analyses: careful
monitoring of investigational sites, adherence to ‘‘good clin-
ical practices’’ (GCP) procedures, quality control and quality
assurance standards, and cross-checking of CRF data
against primary medical charts. The FDA performs detailed
statistical and medical reviews of the data, typicallyindependent, complete re-analyses e none of which are
usually available when reports are submitted for peer re-
view. As practicing clinicians must determine their use of
approved therapies based on a wide variety of publications
and labeling information, a better understanding of the
regulatory approval process is relevant. In view of the
well-recognized need for OA treatments with minimal
systemic toxicities, and the documented safety proﬁle of
IA-HA products, the information presented here should
help clinicians better evaluate a controversial therapy.
Methods
RCTs INCLUDED IN THE ANALYSIS
Summary data from 18 clinical trials evaluating a single
IA-HA product (Supartz, manufactured by Seikagaku Cor-
poration, Tokyo, Japan, and distributed by Smith & Nephew
Orthopaedics, Memphis, TN, USA) were included in a Pre-
Marketing Approval application (PMA). Of these, ﬁve were
double-blind RCTs conducted in compliance with GCP re-
quirements, and considered to meet FDA criteria for review.
Individual study reports for eachRCTwere submitted, includ-
ing protocol, individually completed CRFs, full data sets, and
analyses of safety and efﬁcacy. This entire data set, including
original CRFs, was made available to the authors for this in-
tegrated analysis. The RCTs were conducted in Germany
(1991), Sweden (1993), France (1995), United Kingdom
(1996), and Australia (1996); they are summarized in
Table I and will be referred to in the manuscript by country
of origin. Several of the current authors served as primary in-
vestigators in these trials.
TRIAL DESIGN OVERVIEW
All ﬁve RCTs were similar in design: prospective, ran-
domized, placebo-controlled, and evaluated a treatment
regimen of 5 weekly arthrocenteses and injections of either
active HA or ‘‘placebo’’ (phosphate buffered saline). One
trial (Germany) used a dilute (0.01%) HA formulation as
the control injection instead of saline. Another (France)
evaluated a three-injection in addition to a ﬁve-injection reg-
imen of IA-HA. All RCTs followed patients for at least 3
months (Table I). Efﬁcacy was assessed at weeks 5 and
13 after the ﬁrst injection in all and at week 9 in four trials;
there were additional evaluations at weeks 17, 20 and/orTable I
Comparison of patient populations, outcome measures, and evaluation time points utilized in the individual trials and the integrated analysis
Country [Reference] No. of centers No. of patients Outcome measures Evaluation
time points
Total HA Control Primary Secondary
Australia [Day et al.11] 17 223 108 115 WOMAC
pain scale
Leque`sne;
global assessment;
rescue medication
Weeks 5, 9, 13
and 17
France [unpublished] 54 254 (5) 87
(3) 87
80 LI VAS pain;
global assessment;
rescue medication
Weeks 5, 9 and 13
Germany [Puhl et al.10] 25 208 102 106 LI VAS pain; global
assessment
Weeks 5, 9 and 13
Sweden [Lohmander et al.12] 8 239 119 120 LI VAS pain global
assessment;
rescue medication
Weeks 5, 13 and 20
UK [unpublished] 19 231 116 115 VAS pain VAS pain; LI global
assessment
Weeks 5, 9, 13,
17 and 25
Integrated data set 123 1155 619 536 LI Weeks 5, 9 and 13
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format and collected identical outcome measures in all tri-
als, although varied in language and some speciﬁc details.
All RCTs were conducted in accordance with the Declara-
tion of Helsinki and appropriate Institutional Board Review;
all patients provided written informed consent.
PATIENT POPULATIONS
The ﬁve RCTs enrolled patients with symptomatic OA,
40 years old (50 in Sweden), with radiographically con-
ﬁrmed OA of the tibiofemoral compartment. Predominantly
unilateral disease was speciﬁed in all but one RCT
(Germany), with differences across trials in precise inclu-
sion criteria deﬁning symptomatic severity and radiologic
changes at baseline. All protocols excluded patients if
they had inﬂammatory arthropathies, IA injections during
the prior 3e6-month period, clinically relevant instability or
malalignment and/or severe effusion. Severe knee effu-
sions were excluded in all but the Swedish trial; deﬁned
as >50 ml at baseline in the UK and Australia protocols,
>100 ml in Germany, and clinically as a ‘‘tense distended
effusion’’ in France. Trials in Australia, the UK, and Ger-
many excluded patients with morbid obesity.
OUTCOME MEASURES
All ﬁve RCTs used validated outcome measures sensitive
to change, accepted for use in OA clinical trials and cited in
the FDA July 1999 draft Guidance for Industry: Clinical
Development Programs for Drugs, Devices and Biological
Products Intended for the Treatment of Osteoarthritis (sum-
marized in Table I)13e16. The LI was the primary endpoint in
three trials and a secondary endpoint in the other two trials.
All ﬁve trials included an investigator global assessment of
disease activity; four trials included a patient global assess-
ment of disease activity and patient reported pain by visual
analog scale (VAS). In the Australian study, the Western
Ontario and McMaster Universities Osteoarthritis (WOMAC)
index was the primary endpoint; in the UK trial, the primary
endpoint was patient assessment of pain by VAS. All RCTs
quantitated use of rescue medication with acetaminophen
(co-proxamol: 325 mg of acetaminophen with 32.5 mg
of dextropropoxyphene in the UK trial) as a secondary
outcome measure. Concomitant non-steroidal anti-
inﬂammatory drug (NSAID) use was prohibited in all trials.
POOLED DATA SET
Data derived from original CRFs in the ITT population
were used to assemble a pooled data set, with last observa-
tion carried forward (LOCF) to handle missing data. Data
were included from all post-treatment time points common
to the ﬁve trials: weeks 5, 9 and 13 post-treatment. The
LI, a composite measure of pain and function validated for
RCTs of knee OA, was used as the primary outcome mea-
sure because it was the only disease-speciﬁc outcome
instrument common to all trials. Data from the French study
pooled patients receiving three HA injections (plus two
saline injections) and ﬁve HA injections into a single active
(A) treatment group.
STATISTICAL METHODS
As all studies included repeated measures of treatment
effects, the integrated analysis used longitudinal data analy-
sis models, which test for effects of treatment over time.Two statistical approaches using ﬁxed and random effects
models were applied to evaluate robustness of the analy-
ses. The SAS PROC MIXED procedure was used, which
utilizes the Laird and Ware approach to analyze repeated
measures17. Both approaches offer increasing statistical
power for improved estimates of active treatment effect. If
similar results are achieved using these different models,
robustness of the analyses is demonstrated.
The choice of statistical models addressed the appropri-
ateness of pooling data from different RCTs. A lack of sta-
tistically signiﬁcant treatment-by-study interactions would
provide conﬁdence in the interpretation of pooled results,
especially if unadjusted treatment and estimated effects
derived from the analysis models were similar.
TERMS IN MODEL AND INTERACTION EFFECTS
For the integrated analysis, longitudinal data were inter-
preted using SAS PROC MIXED, based on changes from
baseline in LI as the dependent variable and treatment group;
baseline Leque`sne total score, visit, study, visit-by-treatment
interaction; and study-by-treatment interaction as indepen-
dent variables. In addition, center andcenter-by-treatment ef-
fects were nested in the study and study-by-treatment as
independent variables. Speciﬁcally, the model for integrated
analysis of Leque`sne scores across all RCTs was
C LEQ¼ TRTþWEEKþ LEQALLBþSTUDY
þCENTERðSTUDYÞ þSTUDYTRTþTRT
WEEKþCENTERTRTðSTUDYTRTÞ
where C_LEQ is change from baseline in Leque`sne total
score, TRT the treatment group, and LEQALLB baseline
Leque`sne total score.
Twomodelswereused: the ﬁrstmodel treatedall terms that
included STUDY (i.e., STUDY, CENTER(STUDY),
STUDY TRT, and CENTER TRT(STUDY TRT) as
ﬁxed effects; the secondmodel treated all terms that included
STUDY as random effects. Variance components were esti-
mated using the method of maximum likelihood in the ﬁrst
model and the method of moments in the second model. If
any of the interaction terms were not statistically signiﬁcant
at the 0.10 level, they were excluded from the model.
Results
TRIAL QUALITY SCORES
The ﬁve trial reports were assessed for quality by two
authors (VS and PB) using the scale proposed by Jadad
et al.18. This scale assigns 1 point for randomization, 1 point
for double-blinding, 1 point for proper description of all with-
drawn patients, 1 point if the randomization method was
appropriate (1 if inappropriate) and 1 point if the double-
blinding was appropriate (1 if inappropriate). All trials
scored the full 5 points on the Jadad scale, as all utilized
computer-generated randomization codes blocked by site,
and a blinded evaluator that did not perform injections to
maintain allocation concealment. In fact all assessment cri-
teria proposed by Jadad are measures routinely required for
RCTs accepted by FDA.
PATIENT DISPOSITION
The ﬁve trials included in these analyses enrolled 1155
patients: 619 received IA-HA and 536 control injections.
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(14.6%) treatment groups were low (Table II), and lower
in the HA group in all ﬁve individual RCTs. Discontinuations
due to an adverse event were low (1.8% in HA and 3.2% in
control groups) and lower with HA treatment in four of ﬁve
studies. In the UK study, more discontinuations due to an
adverse event were reported in HA (5.5%) compared with
control (3.8%) treatment. It should be noted that the highest
overall percentage of discontinuations occurred in the UK
trial, statistically favoring IA-HA over control in a Kaplane
Meier survival analysis (28.3% vs 40.9%, data not shown).
PATIENT CHARACTERISTICS AT BASELINE
Table III presents the patient population in the ﬁve individ-
ual RCTs and pooled data set, typical of OA trials in mean
age, preponderance of females, and tendency toward ele-
vated body mass index (BMI). Demographic and baseline
disease characteristics were similar across trials, between
treatment groups in individual trials, and across the
Table II
Patient disposition, ITT population, for the pooled data set from the
five RCTs included in integrated analysis (N¼ number randomized)
Treatment group
Disposition Placebo
(N¼ 536)
HA, 3 or 5 injections
(N¼ 619)
n % n %
Completed study 458 85.4 556 89.8
Discontinued early 78 14.6 63 10.2
Reason for discontinuation*
Adverse event 17 3.2 11 1.8
Did not fulﬁll
entry criteria
10 1.9 9 1.5
Intercurrent illness 10 1.9 8 1.3
Lack of efﬁcacy 4 0.7 7 1.1
Lost to follow-up 3 0.6 9 1.5
Non-compliance 1 0.2 2 0.3
Patient decision 25 4.7 18 2.9
Protocol violation 5 0.9 5 0.8
Other 25 4.7 8 1.3
*More than one reason was allowed.integrated data set. Several speciﬁc differences between
the RCTs should be noted: statistically more women were
included in the active treatment group in Germany, and
more patients in the Australian and UK trials were included
with higher baseline LI scores. Regardless, there were no
statistically signiﬁcant differences between active and con-
trol groups in the pooled ITT treatment population used
for the integrated analysis.
EFFICACY ANALYSES
Tables IV and V present results of the integrated analysis
using repeated measures ﬁxed and random effects models.
Statistical signiﬁcance of covariates and interaction terms
contributing to the model are presented in Table IV: treat-
ment, week, study, and baseline LI scores were signiﬁcant
in both models. With the exception of treatment by week
using the random effects model, interaction terms in the
model were not statistically signiﬁcant, meaning there
were no study or center treatment interactions. By the ﬁxed
effects model, improvement from baseline in mean
Leque`sne scores was estimated at 2.74 for HA compared
with 2.16 for the control group. This represents a statisti-
cally signiﬁcant difference between treatment groups of
0.58 (P¼ 0.0026, 95% CI: 0.95 to 0.20). In the random
effects model, improvement from baseline in LI scores was
2.68 for HA compared with 2.00 for control treatment;
this 0.68 difference was statistically signiﬁcant (P¼
0.001, 95% CI: 0.79 to 0.56). Use of rescue medications
was similar in both treatment groups when analyzed by ei-
ther model (data not shown). The effect size of this be-
tween-group difference was 0.20, calculated as the mean
difference divided by the pooled standard deviation.
Table VI provides results for the individual studies using
the same statistical model applied to the integrated analy-
sis. Using this standard PROC MIXED (SAS) analysis, sta-
tistical signiﬁcance was evident only in the Australian and
UK studies and was approaching signiﬁcance in the French
study (P¼ 0.06091). Statistical analyses of the French and
German studies were sensitive to the model tested. The
Swedish study demonstrated no statistically signiﬁcant dif-
ferences for the ITT population in any of the models tested.
Various assumptions on correlation structures, including
compound symmetry, independence, and unstructured,
were tested and yielded similar results (data not shown).Table III
Demographics and baseline disease characteristics by treatment group in the ITT population of the individual trials and the integrated data set
Trial data set Age (mean) % Female BMI Baseline total Leque`sne
Australia [Day et al.11] A¼ 62.4 A¼ 56.5 A¼ 29.5 A¼ 12.1
C¼ 63.0 C¼ 61.7 C¼ 29.2 C¼ 13.0
France [unpublished] A (5)¼ 64.7 A (5)¼ 60.9 A (5)¼ 27.4 A (5)¼ 9.8
A (3)¼ 63.9 A (3)¼ 73.6 A (3)¼ 28.3 A (3)¼ 9.8
C¼ 65.2 C¼ 68.8 C¼ 28.5 C¼ 10.1
Germany [Puhl et al.10] A¼ 62.0 A¼ 70.6* A¼ 26.2 A¼ 10.5
C¼ 60.5 C¼ 56.6 C¼ 26.8 C¼ 9.6
Sweden [Lohmander et al.12] A¼ 58.5 A¼ 55.5 A¼ 27.7 A¼ 9.9
C¼ 58.0 C¼ 55.8 C¼ 27.2 C¼ 9.6
UK [unpublished] A¼ 60.8 A¼ 60.3 A¼ 28.7 A¼ 13.5
C¼ 61.6 C¼ 53.9 C¼ 28.2 C¼ 13.5
Integrated data set A¼ 61.8 A¼ 62.4 A¼ 28 A¼ 11.0
C¼ 61.4 C¼ 58.8 C¼ 28 C¼ 11.3
A¼HA group. C¼ control group. (5)¼ Five injections. (3)¼ Three injections.
*Percent female was statistically signiﬁcantly higher in the HA group.
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of the repeated measurements because it produced the
model with overall greatest precision (measured by
Akaike’s Information Criterion).
SAFETY ANALYSES
Table VII lists adverse events reported in the individual
RCTs and pooled data sets. The incidence of adverse
events across active (HA) and control groups in the individ-
ual trials and integrated analysis was similar: 1.8% receiv-
ing HA and 3.2% control injections discontinued treatment
early due to an adverse event (Table II). The incidence of
injection site reactions and/or pain was numerically higher
in the HA group in four of ﬁve trials (Table VI). None were
reported to be serious; all resolved without sequelae; and
none were considered by the investigator to be related to
IA-HA treatment. Table VIII provides a review of the eight
allergic reactions reported in the ﬁve RCTs; none appeared
to be related to HA injections. They included hay fever, cu-
taneous allergy to adhesive tape and an allergic reaction to
an IM injection of diclofenac.
Discussion
Integrated analysis is an analytic technique that can pro-
vide supportive and explanatory evidence. It is particularly
useful when a pivotal study supports the safety and efﬁ-
cacy of a product, but additional studies yield variable re-
sults when examined individually19. The integrated
analysis presented here was included as supportive evi-
dence in the marketing application for an IA-HA product
and differs from reported meta-analyses in several impor-
tant ways. It evaluates a single HA product, based on
data from ﬁve RCTs that were similar in design and out-
come measures. Rather than extracting and transforming
data from published reports, individual patient CRF data
Table IV
Statistical significance of covariates and interaction terms in the
integrated data set using fixed and random effects models
Parameter PROC MIXED P-value
Fixed effects
model
Random effects
model
TRT 0.0026 0.0001
WEEK 0.0055 0.0001
LEQALLB 0.0001 0.0001
STUDY 0.0001 0.0001
CENTER(STUDY) 0.0001 NS
TRTWEEK NS 0.0600
STUDY TRT NS NS
CENTER TRT(STUDY TRT) NS NS
NS¼ not signiﬁcant at 0.10 level.were pooled from the ITT population, according to a single
outcome measure common to all ﬁve trials (LI). Impor-
tantly, the individual RCTs were reviewed by the FDA,
including the integrated analysis and statistical methodol-
ogy, providing additional scientiﬁc support for this analysis
of efﬁcacy and safety that is frequently unavailable during
peer review.
Comparing IA-HA and control groups, the integrated
analysis showed statistically signiﬁcant improvement favor-
ing active treatment. Statistical models employed ac-
counted for treatment effects by visit, baseline score,
study, center nested within study, study-by-treatment
interactions, visit-by-treatment interactions, and center-
by-treatment nested within study-by-treatment. Importantly,
similar statistical conclusions were obtained using both
ﬁxed and random effect models, supported by a variety of
correlation structure assumptions. Together, the combined
analyses conﬁrm the efﬁcacy of active IA-HA treatments
and demonstrate the conclusions are robust.
Based on this integrated analysis, a 24% improvement in
Leque`sne scores from baseline is evident in IA-HA com-
pared with 17.7% in saline control groups. Improvement
with IA-HA injections compares favorably with that reported
for treatment with cyclooxygenase-2 selective NSAIDs,
non-selective NSAIDs and acetaminophen in RCTs of
knee OA. The magnitude of mean improvement from base-
line for IA-HA treatment meets criteria for minimum clinically
important difference (MCID) deﬁned based on intra-group
mean improvements from baseline in recent RCTs of thera-
peutic agents commonly used in knee OA15.
With respect to safety parameters, this integrated analy-
sis conﬁrmed that patients receiving IA-HA injections expe-
rienced no systemic adverse events related to treatment.
Table VI
Mean reductions in LI score from baseline for the individual studies,
and significance of the treatment effect using the integrated analy-
sis statistical model
Country [Reference] LI improvement PROC MIXED
P-value
Australia [Day et al.11] A¼ 2.85 0.0114
C¼ 1.98
France [unpublished] A (5)¼ 3.08 0.06091
A (3)¼ 3.14
C¼ 2.64
Germany [Puhl et al.12] A¼ 3.87 0.5489
C¼ 2.74
Sweden [Lohmander
et al.12]
A¼ 1.68 0.4553
C¼ 1.77
UK [unpublished] A¼ 2.19 0.0223
C¼ 1.53
A¼HA group. C¼ control group. (5)¼ Five injections. (3)¼
Three injections.Table V
Estimates of treatment effect in the integrated analysis using fixed and random effects models (PROC MIXED)
Treatment Fixed effects model Random effects model
Estimate Standard error 95% CI Estimate Standard error 95% CI
HA 2.74 0.17 (3.07, 2.41) 2.68 0.04 (2.76, 2.60)
Control 2.16 0.18 (2.51, 1.82) 2.00 0.04 (2.09, 1.93)
Difference: HA control 0.58 0.19 (0.95, 0.20) 0.676 0.057 (0.79, 0.56)
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Adverse events in the individual trials and integrated data set
Country [Reference] Injection site disorder Arthralgia
(%)
Arthropathy/Arthrosis/
Arthritis (%)
Back pain
(%)
Pain
(%)
Headache
(%)
Site reaction (%) Site pain (%)
Australia [Day et al.11] A¼ 4.6 A¼ 10.2 A¼ 25.0 A¼ 15.7 A¼ 16.7 A¼ 0.9 A¼ 13.0
C¼ 2.6 C¼ 7.8 C¼ 26.1 C¼ 8.7 C¼ 9.6 C¼ 2.6 C¼ 12.2
France [unpublished] A (5)¼ 2.3 A (5)¼ 6.9 A (5)¼ 18.4 A (5)¼ 3.8 A (5)¼ 11.5 A (5)¼ 16.1 A (5)¼ 6.3
A (3)¼ 1.1 A (3)¼ 3.4 A (3)¼ 12.6 A (3)¼ 9.2 A (3)¼ 12.5 A (3)¼ 18.4 A (3)¼ 10.3
C¼ 0.0 C¼ 5.0 C¼ 15.0 C¼ 1.1 C¼ 7.8 C¼ 20.0 C¼ 3.4
Germany [Puhl et al.10] A¼ 0.0 A¼ 0.0 A¼ 4.9 A¼ 2.0 A¼ 0.0 A¼ 0.0 A¼ 0.0
C¼ 0.0 C¼ 0.0 C¼ 3.7 C¼ 0.9 C¼ 0.0 C¼ 0.0 C¼ 0.0
Sweden [Lohmander
et al.12]
A¼ 15.8 A¼ 0.8 A¼ 29.4 A¼ 30.3 A¼ 0.0 A¼ 0.0 A¼ 0.0
C¼ 10.0 C¼ 0.0 C¼ 25.8 C¼ 28.3 C¼ 0.0 C¼ 1.7 C¼ 0.8
UK [unpublished] A¼ 6.0 A¼ 4.3 A¼ 13.8 A¼ 3.4 A¼ 4.3 A¼ 5.2 A¼ 0.9
C¼ 2.6 C¼ 7.8 C¼ 15.7 C¼ 9.6 C¼ 4.3 C¼ 4.3 C¼ 2.6
Integrated data set A¼ 6.9 A¼ 4.2 A¼ 17.4 A¼ 11.0 A¼ 7.1 A¼ 6.0 A¼ 4.8
C¼ 3.4 C¼ 2.8 C¼ 17.7 C¼ 10.6 C¼ 4.2 C¼ 4.9 C¼ 3.9
A¼HA. C¼Control. (5)¼ Five injections. (3)¼ Three injections.Injection site reactions were not signiﬁcantly different in
characteristics or severity from those observed after saline
control injections. Differences between trials in reported
rates of injection site reactions and arthralgia may reﬂect
cultural differences. No signiﬁcant allergic reactions to IA-
HA treatment were observed despite 5 consecutive weekly
injections. These data compare favorably with reports of
systemic adverse events in 1e2% of patients treated with
other HA products, including generalized urticaria and cuta-
neous vasculitis20,21.
Overall discontinuation rates in the combined ITT popula-
tion across all ﬁve RCTs were low and compare favorably
against published RCTs for other IA-HA treatments of OA.
We report a discontinuation rate of 10.2% for the IA-HA
group compared with 14.6% for control, similar to overall
discontinuation rates of 12.4% described in meta-analyses
of IA-HA trials and in individual study results4,22,23.
The calculated effect size determined in this comparison
of IA-HA to saline injections was 0.20, in the low range and
comparable to that reported in standard meta-analyses of
IA-HA trials4. This effect size is also comparable to that re-
ported for NSAIDs compared with acetaminophen, and was
considered as evidence favoring utilization of NSAIDs24. To
place this calculated effect size in context, it is important toconsider the inherent challenges of RCTs evaluating the ef-
ﬁcacy of IA treatments for knee OA. The ‘‘placebo’’ control
in such trials is quite different from the placebo control in
RCTs of orally administered agents. The effectiveness of
arthrocentesis and saline injection to relieve pain in knee
OA is long known to clinical researchers25. A ‘‘placebo’’ ar-
throcentesis is certainly an effective treatment for patients
presenting with signiﬁcant effusion26. Thus, it is appropriate
to consider the ‘‘placebo’’ procedure utilized in these ﬁve
RCTs as an ‘‘active’’ control, having potential clinical beneﬁt
for some patients that exceeds a matched placebo pill. Clin-
ical trials of IA corticosteroids uniformly ﬁnd that statistically
signiﬁcant superiority over saline injections can only be
demonstrated for up to 2e4 weeks post-injection27. None-
theless, IA-corticosteroid injections remain an important
option in the clinician’s arsenal for managing patients with
knee OA.
When statistical models used in these integrated analysis
were applied to the ﬁve trials individually, the conclusion
reached for the German study differed from that reported
in the original publication (Puhl et al.), citing statistically sig-
niﬁcant differences in LI favoring administration of this IA-
HA product following the third injection to week 1410. Similar
discrepancies were reported in two recent CochraneTable VIII
Detailed analysis of reported allergic reactions in all treatment groups
Study/Patient no. Treatment group Investigator description Duration (day) Relatedness Severity Action
Australia/00067 Control Allergic reaction on scalp
to adhesive plaster
Continued to study end Not related Mild Treatment
commenced
Australia/00093 Active Hay fever 50 Not related Mild Treatment
commenced
Australia/00188 Active Hay fever 1 Not related Mild None
Australia/00250 Active Allergy reaction 1 Not related Mild None
France/00153 Active (3 injections) Allergy face/neck 35 Not related Mild None
France/00154 Control Allergic cough 3 Not related Moderate None
France/00373 Active (3 injections) Cutaneous allergy
forearms and knees
21 Not related Mild None
Germany/00211 Control Allergic reaction after IM
injection of diclofenac and
dexaphlogont because of
acute lumboishialgia
(injected by GP)
1 Not related Severe Cessation of
treatment
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ferences between RevMan and originally published analy-
ses of the same trials6,27. In the German study reported
here, this difference can be largely attributed to differences
between the per protocol population previously reported
and the ITT population, as well as the way identiﬁed cova-
riates were treated in the utilized statistical models.
More rigorous ITTanalyses of individualRCTs facilitate ex-
ploration of the way RCT designs may inﬂuence results. The
German and Swedish trials differed from the other three trials
in several important features e only the German trial did not
specify patients with unilateral or predominantly unilateral
knee OA. Because IA-HA treatment rarely has systemic ef-
fects,musculoskeletal symptomsat sitesother than thespec-
iﬁed symptomatic knee can affect the ability of patients to
judge improvement in their designated joint, thereby con-
founding analysis of between-group differences. Only the
Swedish trial did not exclude patients with clinically relevant
instability or malalignment of the study knee, which may
also confound between-group differences.
Another important difference between the ﬁve RCTs
worth noting is how patients with effusion at baseline
were handled. They were not excluded in the Swedish trial
and only excluded in the German study if they presented
with a baseline effusion greater than 100 ml. The UK and
Australian trials set the exclusion criteria for effusion at
50 ml, and the French trial excluded patients with a clinically
deﬁned ‘‘tight distending effusion’’. Trials of other IA-HA
agents are likewise inconsistent with respect to the exclu-
sion of patients with knee effusion20,22,28e32. This suggests
that exclusion of patients with signiﬁcant baseline effusions
may be an important factor underlying the variability re-
ported in RCTs of IA-HA products.
It is important to note several limitations of our analysis
and its interpretation. The analysis includes only the ﬁve
multinational phase 3 RCTs conducted in accordance with
GCP by the manufacturer in support of their marketing ap-
plication, two of which were never published. This inte-
grated analysis is also subject to problems associated
with pooling of data from trials that may have important dif-
ferences in design or patient population, limitations inherent
in any meta-analysis. Another limitation arises from the use
of covariates and interaction terms, which cannot correct for
known and unknown confounding factors to the same ex-
tent as randomization within an individual RCT.
OA of the knee presents an increasing burden on health-
care systems for which the therapeutic armamentarium re-
mains limited. Though NSAIDs remain the most utilized
treatment for patients who fail conservative therapy, their
long-term administration is accompanied by signiﬁcant mor-
bidity. The analysis we report here conﬁrms the statistically
signiﬁcant difference between IA-HA and saline injections,
demonstrates that the effectiveness of IA-HA is comparable
to other OA treatments based on the improvements from
baseline, and highlights the safety advantages of a local
treatment with no systemic actions. Additional work remains
to better deﬁne the population responsive to IA-HA, and op-
timize its cost-effectiveness as part of a conservative strat-
egy for disease management.
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